Survodutide 10 mg

Survodutide is being investigated for obesity and metabolic dysfunction-associated steatohepatitis (MASH). It is a dual glucagon/GLP-1 receptor agonist designed to combine appetite suppression with increased energy expenditure and liver fat reduction. It is not approved for any indication, and this product is supplied for laboratory research only.

Head-to-head trials have not been conducted, so a direct comparison is not possible. In separate Phase 3 trials, survodutide produced 12.2–13.0% weight loss at 76 weeks in adults with obesity without diabetes, while tirzepatide produced up to 21.9% at 112 weeks in its SURMOUNT-MAINTAIN trial. These are different populations, durations, and trial designs. Survodutide's glucagon component may offer additional liver benefits, but this remains under investigation.

In the Phase 3 SYNCHRONIZE-1 trial (adults with obesity, no diabetes), mean weight loss at 76 weeks was 12.2% (3.6 mg) and 13.0% (6.0 mg) versus 5.4% for placebo. In SYNCHRONIZE-2 (adults with obesity and type 2 diabetes), weight loss was 8.2% (3.6 mg) and 9.8% (6.0 mg) versus 3.9% for placebo. These are investigational drug results from controlled trials, not data from self-administered research vials.

Gastrointestinal adverse events are the most common: 80.9% (3.6 mg) to 89.7% (6.0 mg) of treated participants in the obesity trial reported nausea, vomiting, diarrhea, or constipation, compared to 47.9% on placebo. In the diabetes trial, 18% of survodutide recipients discontinued due to GI events versus 1.2% on placebo. Most events were mild to moderate and occurred during dose escalation.

No. Survodutide is investigational and has not been approved by the FDA, EMA, or any other regulatory agency. Phase 3 trials have been completed with positive results, but regulatory submission and review have not occurred. This Dragon Pharma product is a research peptide, not an approved medicine.

One COA is supplied. The September 2024 test of batch SVDHD7 measured 9.68 mg per vial, which is 96.8% of the labeled 10 mg. Lab results reflect the specific batch tested and do not guarantee other batches.

Store the lyophilized powder refrigerated (2–8°C) or frozen (-20°C), protected from light and moisture. Allow vials to reach room temperature before opening to prevent condensation. After reconstitution, refrigerate and use according to your laboratory protocol. Avoid repeated freeze-thaw cycles. No manufacturer-verified stability data was supplied for this specific batch.

Semaglutide targets only the GLP-1 receptor. Survodutide adds glucagon receptor activity, which is intended to increase energy expenditure and directly reduce liver fat. This dual mechanism is being explored for MASH as well as obesity. Semaglutide is FDA-approved for diabetes and obesity; survodutide is not approved for any indication.